Background: Freezing of gait (FOG) is a common symptom in patients with advanced Parkinson's disease (PD) representing a major cause of disability and falls. Although the pathophysiology of FOG remains poorly understood, nondopaminergic pathways have been implicated. Treatment studies of levodopa and selegiline have shown limited benefit for FOG. Limited data suggest that amantadine, an N-methyl-Daspartate receptor antagonist, may be beneficial for FOG in PD.
F reezing of gait (FOG) occurs in 53% of patients with advanced Parkinson's disease (PD). This symptom is a major source of disability and is associated with increased risk of falls and injuries in the PD population. 1 The pathophysiology of FOG is poorly understood but is thought to be driven by both dopaminergic and nondopaminergic pathways. 2 Although levodopa can improve FOG in patients with PD, improvement in FOG correlates poorly with improvement in rigidity, bradykinesia, and postural instability. 2 With progression of PD, patients develop fluctuations in motor symptoms, which are partly related to the timing of medication administration. With the administration of medications, symptoms improve temporarily (''on'' state). When the medication wears off, symptoms worsen (''off'' state) until another dose of medication is taken. Freezing of gait is most commonly observed in the medication ''of'' state; ''off'' FOG can respond to dopaminergic therapy, particularly in early stages of PD. However, medication-resistant FOG that persists in the ''on'' state despite improvement of other parkinsonian symptoms is more frequent in advanced stages of PD and is challenging to treat.
There are limited treatment options for gait dysfunction, specifically FOG. Various medications have been tried to treat FOG but have shown limited benefit. In patients with PD and motor fluctuations, levodopa improves ''off'' FOG but may occasionally result in ''on'' FOG. 2 In one study, selegiline, a monoamine oxidase-B inhibitor, was associated with mild improvement in FOG and reduced the risk of developing FOG, but other studies have yet to confirm this finding. 3 A home physical therapy program using rhythmical cueing on gait and gaitrelated activity was associated with a small but transient benefit in freezing severity, gait speed, step length, and timed balance. However, this effect attenuated over 6 weeks if cueing was not continued. 4 Amantadine is approved as adjunctive treatment for PD. The mechanism of action of amantadine is unclear but is thought to involve antagonism of N-methyl-D-aspartate (NMDA) receptors and inhibition of dopamine reuptake. 5, 6 Whereas some data suggest that amantadine is associated with lower risk of FOG, results are conflicting. 1, 7, 8 The objective of this study was to examine the relationship between orally administrated amantadine and change in FOG among patients with PD taking amantadine specifically for FOG. We hypothesized that treatment with oral amantadine is associated with improvement in FOG in patients with PD.
MATERIALS AND METHODS
We conducted a retrospective chart review of patients with PD treated with amantadine for FOG associated with PD at Northwestern University PD and Movement Disorders Center between January 2, 2004 and February 25, 2009. The protocol was approved by the Northwestern University Institutional Review Board. Eligible patients had to have at least one follow-up visit after initiation of amantadine to assess FOG. Patients with records lacking documentation of treatment response were not eligible for study participation. Based on documentation, we were not able to distinguish whether FOG was in ''on'' and/or ''off'' states.
The primary outcome measure was subjective self-report about FOG during a follow-up visit after initiating amantadine, classified as improved, worsened, or static FOG. Additional outcomes included duration of the clinical effect and adverse effects associated with amantadine use. Patient demographics and disease characteristics recorded included age, sex, age of PD onset, PD duration, Hoehn and Yahr stage, levodopa equivalent daily dose (LEDD), amantadine dose and frequency, and duration of treatment. 9 Descriptive statistics including frequencies, means, and standard deviations were performed for outcome measures and patients' characteristics using SPSS version 16 (SPSS Inc, Chicago, IL).
RESULTS
Two hundred thirty-six patients were treated with amantadine throughout the study period. Of this group, 196 patients had a diagnosis of PD, and 171 patients were given amantadine at the Northwestern University PD and Movement Disorders Center. Twelve patients were given amantadine specifically for FOG; 11 of these patients had a follow-up visit. The remaining 159 patients were excluded because they were given amantadine for another indication (tremor, 72; dyskinesia, 49; fatigue, 3; rigidity, 2 patients) or the indication was unclear (33 patients). Patients' characteristics, treatment duration, amantadine dose, and response are presented in Table 1 . The median age of PD onset and PD duration were 67 years (range, 51Y84 years) and 4 years (1Y11 years), respectively. Median Hoehn and Yahr stage was 3 (range, 2Y4). One of the 11 patients was female. Median LEDD was 475 mg (range, 0Y1348 mg). Median amantadine dosage was 100 mg twice daily (range, 100 mg once daily to 100 mg twice daily), and median duration of therapy was 20 months (range, 6Y66 months).
Ten of 11 patients reported subjective improvement in FOG after initiating amantadine. Treatment with amantadine was associated with worsening of FOG in one patient (no. 2). In another patient (no. 10), FOG initially improved but the benefit plateaued; the amantadine was therefore discontinued, but the patient soon developed worsening of FOG, so amantadine was restarted, and the patient reported subjective improvement of gait. Four patients reported attenuation of benefit within 4 months. Two patients reported adverse effects resulting in discontinuation of amantadine. Patient no. 8 developed lower extremity edema within 5 months, which resolved when amantadine was discontinued. Patient no.11 developed hallucinations in the first 2 months of treatment, which persisted despite reduction in amantadine dosage from 100 mg twice daily to 100 mg once daily. Amantadine was therefore discontinued; however, this patient was also taking ropinirole and carbidopa/levodopa, which may have contributed to the hallucinations. Patient no. 7 reported blurred vision and temporarily stopped taking amantadine but resumed it after 1 month.
DISCUSSION
In our cohort, 10 of the 11 patients had subjective improvement in FOG after initiating treatment with oral amantadine. Four patients noted reduction in benefit after approximately 4 months. Adverse effects included visual hallucinations and peripheral leg edema, both of which have been reported. 8 Conflicting available data suggest that amantadine may be beneficial for FOG. A retrospective study demonstrated an association between longer duration of treatment with amantadine and decreased appearance of FOG; however, this association was seen in the univariate but not multivariate analysis. 1 recent investigation showed subjective improvement in FOG as assessed by the FOG-questionnaire with intravenous amantadine at a dosage of 200 mg twice daily for 2 days. 10 Improvement was seen in patients with FOG refractory to dopaminergic therapy, further supporting the concept that FOG may involve nondopaminergic mechanisms. However, underlying clinical diagnoses in that study were heterogeneous (PD, multiple system atrophy, progressive supranuclear palsy, and primary FOG), and responders had a lower age of disease onset. 10 In contrast, a case control study of 6620 patients with PD suggested that amantadine may be associated with the presence of FOG. 7 The results of our study suggest that oral amantadine may be beneficial for FOG associated with PD. Whereas other studies examined the effect of amantadine on the development of FOG in patients with PD, our study and the study of intravenous amantadine have examined effects on existing FOG.
Although the mechanism of action of amantadine in PD is unclear, it may affect multiple pathways. In our study, response in FOG to amantadine was seen across the range of disease severity and large range of LEDD, suggesting that the mechanism of benefit in FOG from amantadine may include dopaminergic and nondopaminergic mechanisms. Amantadine has been shown to stabilize the NMDA receptor channel in the closed conformation, thus antagonizing this receptor. 5 Amantadine also increases extracellular dopamine levels, an effect that may be due to NMDA receptor inhibition. 6 Additionally, studies in rat pheochromocytoma suggest that amantadine may stimulate gene expression of L-amino acid decarboxylase, the enzyme responsible for converting levodopa to dopamine. 11 We recognize several limitations of this study. First, the sample size was small. Second, the data collection was retrospective and assessments were subjective and qualitative. Third, this study was not controlled; at least some of the improvement may be due to placebo effects. Fourth, the physicians used a relatively small dose of amantadine so dose-response effect was not explored. Finally, ''off '' freezing and ''on'' freezing were not distinguished. Despite these limitations, this study provides the pilot data for further evaluation of the relationship between amantadine and FOG.
In summary, the results of this study indicate that amantadine is associated with self-reported improvement in FOG in patients with PD. The benefit, however, may be transient. Amantadine was well tolerated with occasional adverse effects at the dosage of up to 200 mg daily. A randomized controlled trial examining the relationship between FOG and amantadine using objective measures is warranted and is underway.
